title: Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors.
abstract: OBJECTIVE
  To investigate whether early-assessed radioresponse of tumors corresponds with late-assessed radioresponse, which is associated with local disease control in radiotherapy (RT) for cervical cancer.
  
  
  METHODS
  This prospective study included 12 patients with cervical squamous cell carcinoma treated by RT with or without concurrent cisplatin. Tumor volume was estimated by scheduled magnetic resonance imaging before (preRT), 3 to 4 weeks after (early assessment), and 6 to 7 weeks after (late assessment) RT initiation. Radioresponse was assessed with tumor shrinkage curves based on these volumes. Radioresponse for each tumor was calculated as the slope (day(-1)) of the shrinkage curve by fitting to an exponential equation.
  
  
  RESULTS
  Early-assessed radioresponse ranged from 0.001 to 0.106 day(-1) (median, 0.021 day(-1)) and late-assessed radioresponse from 0.009 to 0.091 day(-1) (median, 0.021 day(-1)), with no significant difference between them (p = 0.1191). The early-assessed radioresponse correlated with the late-assessed radioresponse (R(2) = 0.714, p = 0.0005).
  
  
  CONCLUSIONS
  Correspondence between early- and late-assessed radioresponse in a series of tumors showing a wide range of radioresponse was not particularly close overall. However, early assessment of radioresponsiveness did seem to be useful for characterizing those tumors with high or low radioresponsiveness.
authors.affiliation: Department of Radiation Oncology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan. ki-ohara@md.tsukuba.ac.jp
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ohara
authors.forename: Akinori
authors.initials: A
authors.lastname: Oki
authors.forename: Yumiko Oishi
authors.initials: YO
authors.lastname: Tanaka
authors.forename: Kayoko
authors.initials: K
authors.lastname: Onishi
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Fukumitsu
authors.forename: Takayuki
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Toyomi
authors.initials: T
authors.lastname: Satoh
authors.forename: Hajime
authors.initials: H
authors.lastname: Tsunoda
authors.forename: Masaharu
authors.initials: M
authors.lastname: Hata
authors.forename: Shinji
authors.initials: S
authors.lastname: Sugahara
authors.forename: Koichi
authors.initials: K
authors.lastname: Tokuuye
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Akine
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshikawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D011446:Prospective Studies; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin